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Abstract
Background: Translocation of gut-derived bacterial products such as endotoxin is a major problem in liver
cirrhosis.
Methods: To assess the hepatic clearance of bacterial products in individuals with cirrhosis, we tested
concentrations of Gram-negative bacterial lipopolysaccharide (LPS), LPS-binding protein (LBP), and the precursor of
nitric oxide (NO), L-arginine, in a cohort of 8 stable patients with liver cirrhosis before and after elective transjugular
portosystemic shunt (TIPS) implantation, including central venous, hepatic venous, and portal venous
measurements.
Results: Using an adapted LPS assay, we detected high portal venous LPS concentrations (mean 1743 ± 819 pg/
mL). High concentrations of LPS were detectable in the central venous blood (931 ± 551 pg/mL), as expected in
persons with cirrhosis. The transhepatic LPS gradient was found to be 438 ± 287 pg/mL, and 25 ± 12% of portal
LPS was cleared by the cirrhotic liver. After TIPS, central venous LPS concentrations increased in the hepatic and
central veins, indicating shunting of LPS with the portal blood through the stent. This paralleled a systemic
increase of L-arginine, whereas the NO synthase inhibitor asymmetric dimethylarginine (ADMA) remained
unchanged, suggesting that bacterial translocation may contribute to the pathogenesis of circulatory dysfunction
post-TIPS.
Conclusions: This study provides quantitative estimates of the role of the liver in the pathophysiology of bacterial
translocation. The data indicate that the cirrhotic liver retains the capacity for clearance of bacterial endotoxin from
the portal venous blood and that TIPS implantation attenuates this clearance. Thus, increased endotoxin
concentrations in the systemic circulation provide a possible link to the increased encephalopathy in TIPS patients.
Background
Systemic translocation of gut-derived bacteria and their
products is a risk factor for recurrent spontaneous bac-
terial peritonitis and/or encephalopathy in patients with
liver cirrhosis [1,2]. For decades, there has been great
interest in unraveling the pathophysiology of bacterial
translocation in cirrhosis [3]. Experimental data derived
from animal studies demonstrated portal and systemic
bacteremia, predominantly Gram-negative organisms, in
cirrhotic animals with portal hypertension [4-6].
Research conducted 20-30 years ago suggested an
important role for endotoxemia in liver cirrhosis, but
the assays available at that time were less sensitive and
human portal blood sampling is challenging [6,7].
Recent detection of bacterial translocation during HIV
i n f e c t i o n ,t h o u g h tt or e s u l tf r o mi n c r e a s e dg u tp e r m e -
ability, provided a plausible cause of systemic immune
activation; however, parallel studies in, HBV, HCV and
HIV-HCV co-infection demonstrated that bacterial
translocation is strongly associated with cirrhosis, raising
questions of cause and effect [8-11]. In this context, we
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LPS assays [12].
The implantation of a transjugular intrahepatic porto-
systemic shunt (TIPS) has become a standard procedure
for the treatment of complications of portal hyperten-
sion [13,14]. Although of proven benefit in decompen-
sated liver cirrhosis, TIPS is associated with significant
mortality and morbidity from worsened hepatic ence-
phalopathy and hematogenous infections [15]. It is
thought that these complications of TIPS are, in part,
due to the diminished hepatic clearance of bacterial pro-
ducts [16], although the change in clearance has not
been measured. The implantation of TIPS offers an
opportunity to directly quantify LPS in various compart-
ments of the human circulation including the portal
vein [17,18].
Here, we assess concentrations of LPS and the precur-
sor of nitric oxide (NO), L-arginine, in a cohort of
patients with liver cirrhosis undergoing TIPS implanta-
tion to determine the transhepatic LPS gradient in vivo
before and after TIPS [17-19].
Methods
Patients
Plasma samples were collected from 8 consecutive
patients with liver cirrhosis and either refractory ascites,
or recurrent bleeding from varices, undergoing TIPS
placement between 2006 and 2007. Spontaneous bacter-
ial peritonitis was excluded in all patients using ascitic
fluid criteria (< 250 polymorphonuclear cells per μL),
and no patient had systemic infection or active variceal
bleeding. Informed consent was obtained from each
patient included in the study and the study protocol
conforms to the ethical guidelines of the 1975 Declara-
tion of Helsinki as reflected in a priori approval by the
institution’s human research committee.
Methods
Blood was obtained during a standard TIPS procedure.
After cannulation of the internal jugular vein and inser-
tion of a LEV2 catheter (Cook Medical, Germany),
blood was obtained before TIPS from the right atrium
(central venous) and from the hepatic vein close to the
junction with the inferior vena cava. After puncture of
the portal vein, blood was drawn from its trunk.
Approximately 15 min after TIPS placement, blood was
again obtained from the hepatic vein at the junction to
the inferior vena cava. The final blood sample after
TIPS placement was again drawn from the right atrium.
All blood samples were immediately cooled on ice, cen-
trifuged for 10 min under 2,000 g and plasma was
stored at -80°C. All patients were fasting for at least 8
hours before the procedure.
LPS concentrations were measured in plasma diluted
to 1:250 and 1:500 using a Limulus Amebocyte Lysate
assay (LONZA, Walkersville, MD) as previously
described [8], with modifications [12]. For LPS-binding
protein (LBP) measurement, plasma was diluted 1:800
and measured using a commercially available plate-
based ELISA assay according to the manufacturer’ss p e -
cifications (Cell Sciences, Canton, MA).
For quantification of 16s rDNA, DNA was extracted
from a 200 μL aliquot of plasma samples after lysis and
purification using the Roche MagNA Pure system
(Roche Diagnostics, Indianapolis, IN). 16s rDNA was
PCR amplified using a set of universal primers and
probe (forward primer [P891F] 5’TGGAGCATGTGGT
TTAATTCGA; reverse primer [P1033R] TGCGGGACT
TAACCCAACA; UniProbe CACGAGCTGACGACARC
CATGCA) that have been validated as sensitive and spe-
cific for bacterial detection to the limit of 5 pg of con-
taminating DNA [20,21].
L-arginine, asymmetric dimethylarginine (ADMA) and
symmetric dimethylarginine (SDMA) plasma concentra-
tions were determined by liquid chromatography tan-
dem mass spectrometry as recently described [22].
Statistical analyses
The paired t-test was used for inter-group comparisons.
All data are expressed as mean ± SD. P values of 0.05
or less were considered significant.
Results
Patient characteristics are shown in Table 1. No patient
had active variceal bleeding since endoscopic therapy
had been successful weeks ago in the two affected
patients. LPS was detectable in the central venous blood
of all patients before TIPS, although individual concen-
trations were highly variable (mean 931 ± 551 pg/ml).
Before TIPS placement, the LPS concentrations in the
portal vein were higher than in the hepatic vein in all
patients (mean 1743 ± 819 vs. 1319 ± 645 pg/ml, p <
0.05), indicating significant clearance of LPS by the cir-
rhotic liver (Figure 1A-B). Indeed, the mean pre-TIPS
transhepatic endotoxin gradient (THEG) of 438 ± 287,
which was calculated as endotoxin concentration in the
portal vein minus the endotoxin concentration in the
hepatic vein, was consistently found in all patients (Fig-
ure 1B). TIPS insertion was technically successful in all
patients, as demonstrated by fluoroscopy with flow of
the portal venous blood through the stent. In blood
samples taken 15 min after TIPS placement, LPS con-
centrations in the hepatic vein were higher than before
TIPS in all but one patient (mean 1319 ± 645 vs. 1551
± 778 pg/ml p < 0.05). Similarly, central venous LPS
concentrations after TIPS were higher than before
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0.05) (Figure 1A).
To facilitate comparison of individual clearance rates
pre-/post-TIPS insertion in the various compartments,
LPS concentrations were individually normalized to
levels in the portal vein (set as 100% in each patient,
Figure 1C). On average, the pre-TIPS LPS concentration
in the hepatic vein was 75 ± 12%, which corresponds to
a hepatic LPS clearance of 25 ± 12%. After TIPS, the
hepatic vein LPS concentration increased to 92 ± 16%
of the portal vein concentrations, a trend indicating
shunting of LPS with the portal venous blood through
the stent and loss of the THEG. The central venous LPS
concentration increased from 52 ± 10% to 68 ± 15% of
the portal venous concentration (Figure 1C).
LBP is intimately connected with the host response to
LPS, but freely circulates in all blood compartments and
is not expected to be cleared by the liver; therefore, as a
negative control we measured LBP concentrations in the
right atrium, hepatic, and portal vein and found no
transhepatic gradient before or after TIPS (Figure 1C).
Bacterial DNA was measured using a quantitative PCR
assay for 16s rDNA. Bacterial DNA was found in 37/40
tested samples, but there was no relationship or gradient
between 16s rDNA concentrations pre- and post-TIPS
in the various blood compartments (data not shown).
It has recently been shown that the presence of bac-
terial DNA, a marker of bacterial translocation, was
associated with aggravation of NO-mediated peripheral
vasodilation in patients with liver cirrhosis [19]. In addi-
tion NO production resulted from endotoxemia [23].
Thus, we measured L-arginine as an NO precursor in
the various compartments before and after TIPS. In the
portal vein, L-arginine plasma concentrations were
higher than in the hepatic vein before TIPS (77.4 ± 10.0
vs. 51.2 ± 8.1 μmol/l, p < 0.01). After TIPS,
concentrations in the hepatic vein increased to 77.0 ±
11.8 μmol/l, similar to the portal vein levels. Also, the
central venous L-arginine concentration increased from
66.9 ± 12.4 μmol/l pre-TIPS to 78.4 ± 13.2 μmol/l after
TIPS (p < 0.05). Interestingly, concentrations of the
endogenous NO synthase inhibitor ADMA and SDMA
were similar in all compartments before and after TIPS
(p = n.s., data not shown).
Discussion
In healthy individuals, only minimal amounts of endo-
toxin are found in peripheral venous blood, since hepa-
tic macrophages (Kupffer cells) are believed to clear the
endotoxin from intestinal bacteria that enter the portal
vein [3,24-26]. In contrast, endotoxin is frequently
detected in the peripheral blood of cirrhotic patients
resulting from both increased translocation from the gut
and reduced hepatic clearance [27-29]. However, clinical
studies on the pathophysiology of bacterial translocation
and hepatic endotoxin clearance in cirrhosis have been
challenging due to the problem of accessing the portal
vein in humans, emphasizing the demand for new diag-
nostic strategies. Recently, a trial in cirrhotic patients
has shown that presence of bacterial DNA, a marker of
bacterial translocation, was associated with aggravation
of peripheral vasodilation and worsening of intrahepatic
endothelial dysfunction [19]. To further assess the
impact of bacterial translocation in patients with decom-
pensated cirrhosis, we screened a series of patients
undergoing elective TIPS implantation for changes in
endotoxemia before and after shunting blood from the
liver.
A striking difference from previous studies is the high
concentration of systemic endotoxemia detected in our
cohort of patients. The Limulus Amebocyte Lysate
(LAL) assay for LPS quantification has been extensively
Table 1 Patient characteristics
Patient
no
Gender/
age
Cause of
liver
cirrhosis
Indication for TIPS CPS AST/
ALT
(U/l)
MELD
Score
CRP
(mg/dl)
Lactulose
treatment
Systemic
antibiotics
Central venous LPS
before TIPS (μmol/l)
1 f/60 Alcohol Ascites, hepatorenal
syndrome
C 49/32 11 < 5 y y 461
2 m/47 Alcohol Ascites C 83/60 24 < 5 n n 915
3 m/66 Alcohol Ascites, variceal
bleeding
B 43/35 13 26 y n 473
4 m/72 Alcohol Ascites, partial portal
vein thrombosis
A 24/14 7 10 n n 781
5 m/32 PSC Varices, partial portal
vein thrombosis
A 44/56 10 10 n n 622
6 f/48 Alcohol Ascites B 47/14 17 10 y n 847
7 f/40 Alcohol Ascites B 50/15 7 6 n n 1190
8 m/59 Alcohol Recurrent variceal
bleeding, hydrothorax
C 36/16 13 12 y y 2158
Abbreviations: no, number; f, female; m, male; PSC, Primary sclerosing cholangitis; CPS, Child-Pugh Score Class; CRP, c-reactive protein; y, yes; n,n o
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Figure 1 LPS concentrations before and after TIPS. A: Schematic view of the portal and systemic circulation, showing mean LPS quantities
before and after TIPS placement. B: Individual LPS concentrations of the portal and systemic circulation and the transhepatic gradient before
TIPS (* = statistical significant difference) C: Amount of LPS (black bars) and LBP (grey bars) in portal and systemic circulatory compartments
shown as percentage of the values in the portal vein, before and after TIPS.
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serum. We have recently reported that in a cohort of
HIV-infected persons and SIV-infected macaques,
plasma dilutions of ≥ 1:200 were required to diminish
the assay inhibition of plasma, revealing concentrations
comparable with those reported here [12].
Recently, a well-designed trial in patients undergoing
emergency TIPS for uncontrollable variceal bleeding has
examined hemodynamic changes in systemic and cere-
bral blood flow and found systemic endotoxemia to be
associated with increased NO production [18]. The
assessment of systemic LPS concentrations in such
severely ill patients, however, may not be representative
of our cohort, which consists of stable patients receiving
elective TIPS given the strong possibility of transient
endotoxinemia due to instrumentation and bleeding in
the former group [30,31]. Paradoxically, only one-half of
individuals in that study had detectable LPS and even
post-TIPS values were comparatively low [18], which
may be explained by the practice of broad-spectrum
antibiotic administration in persons with acute variceal
bleeding.
We found that the cirrhotic liver cleared 25% of the
endotoxin present in the portal vein. The proportion of
LPS that we measured in the central vein compared to
the portal vein (52 ± 10%) compared closely with a pre-
vious analysis from Lumsden et al. 1988, who deter-
mined that 57% of portal LPS was cleared compared to
the systemic circulation [27]. In contrast, we analyzed
for the first time the THEG between the portal vein and
the hepatic vein directly pre- and post TIPS, which bet-
ter reflects hepatic clearance due to absence of dilution
from the systemic venous circulation. The THEG pre-
T I P Sw a sf o u n dt ob e4 3 8±2 8 7p g / m L ,a n dw a s
remarkably similar between patients despite variable
portal and hepatic vein LPS concentrations in the
cohort. The pre-TIPS THEG we observed strongly indi-
cates that the liver retains the capacity for portal blood
detoxification even in the setting of cirrhosis, but this
may be an underestimate of LPS clearance because cir-
rhosis is frequently associated with reversal of flow,
spontaneous portosystemic shunting, and impaired
clearance of bacteremia. Ideally it would be interesting
to assess the same values in control patients without
liver cirrhosis. However, this is practically challenging,
since access to portal venous and hepatic venous blood
is ethically justified only in persons with a clinical indi-
cation for TIPS placement.
LBP concentrations were not differentially enriched in
the various blood compartments, suggesting that the
transhepatic LPS gradient was not simply an artifact due
to progressive hepatic vein dilution. Since LBP -in con-
trast to LPS- is not specifically cleared by Kupffer cells,
LBP amounts were expected to be the same in the
portal and hepatic veins. LBP is produced by hepato-
cytes, and circulating quantities may be diminished with
extensive hepatic fibrosis and cirrhosis. Reduced LBP
levels may impair LPS sensing systemically, since it is a
key component of the TLR4 receptor complex. The
negative immunologic consequences of reduced LPS
sensing in the context of impaired LPS clearance poten-
tially includes both poor innate immune surveillance
with resulting bacterial infections, as well as reduced
immunotolerance resulting in sepsis-like syndromes;
both are known complications of end-stage liver disease.
Bacterial DNA concentrations were elevated in all
patients, but the levels were not different in the hepatic
and portal vein, suggesting that clearance of bacterial
DNA and LPS occurs via different mechanisms. Markers
of impaired intestinal permeability are elevated in portal
hypertension, particularly with severe liver disease, and
in viral and alcoholic cirrhosis [11,32]. Circulating LPS
levels have indeed been associated with extensive hepa-
tic fibrosis in HCV and HBV infection [8,11]. Therefore,
although we observed an increase in hepatic venous and
systemic endotoxemia in the short term, this may be
reversed in the follow-up period after TIPS placement,
since portal hypertension is reduced. In accordance,
three studies observed reduction of surgical infections
or peritonitis after lowering portal venous pressures
[33-35]. Indeed, it is important to highlight that despite
the patients’ clinical status as having decompensated cir-
rhosis, we found that the liver retains the capacity to
clear translocated bacterial products and that a decrease
in this capacity post-TIPS implantation is associated
with increased NO concentrations. Since no long-term
peripheral endotoxin concentrations are available in our
cohort of patients, future studies should focus on the
potential improvement of endotoxemia and the inci-
dence of infections after TIPS placement.
Endogenous NO is important for the integrity of the
intestinal mucosa, whereas overproduction of NO, e.g.
by inducible NO synthase (iNOS), impairs function of
the intestinal epithelium, increases its permeability and
leads to bacterial translocation and inflammatory
responses [36,37]. Further complicating inference of
cause and effect, bacterial translocation and endotoxe-
mia increase NO production in animal models of cirrho-
sis and in patients [23,38,39]. In accordance with a
recent study focusing on hepatic clearance of NO
synthase inhibitors [40], we found the highest values for
L-arginine in the portal venous blood. Also, L-arginine
concentrations in the hepatic vein and central venous
blood increased after TIPS to a level as high as in the
portal vein. In contrast, the endogenous NOS inhibitor
ADMA was unaltered before and after TIPS. This
increase in NO bioavailability after TIPS placement may
be one of the factors contributing to the hyperdynamic
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from shunting through the TIPS or is a consequence
of reduced cleareance of endotoxin by the liver
remains unclear. It has been suggested that arginase-1
expressing, alternatively activated macrophages regu-
late collagen production and organ fibrosis [41].
Whether the increased L-arginine, which serves as a
substrate for arginase-1, is also involved in alteration
of liver fibrosis is still unclear and needs to be studied
in animal models [42]. However, studies in cirrhotic
patients demonstrated that intestinal decontamination
with antibiotics is associated with less systemic endo-
toxemia and less NO-mediated vasodilatation [23,43],
thus indicating a potential link to the observed changes
after TIPS placement. Since intestinal decontamination
has recently shown to improve encephalopathy and
prognosis in cirrhotic patients [44,45], future studies
should focus on the underlying pathophysiology
including analysis of portal/systemic endotoxin and
NO physiology in patients with cirrhosis. LPS concen-
trations should be correlated with clinical parameters
and outcome, and clinical interventions should be
tested to lower endotoxemia in patients undergoing
TIPS, i.e. by application of prophylactic periinterven-
tional or long-term antibiotics.
Conclusions
Taken together, this small pilot study demonstrates for
the first time a significant transhepatic gradient of LPS
and L-arginine in vivo, and immediate loss of this gradi-
ent following TIPS. These findings also suggest that
measurements of microbial translocation from periph-
eral blood are likely to be both underestimates of intest-
inal translocation and significantly confounded by liver
disease. The liver retains some capacity for LPS clear-
ance even in cirrhosis, and bypassing hepatic LPS may
increase the risk of infection after TIPS. In addition,
future studies of microbial translocation must include
assessment of liver function, particularly in studies of
HIV-infected people in whom liver disease is a major
cause of death [46].
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